I agree we need some direct info on how trials /...

I agree we need some direct info on how trials / commercialisation are going. However i cannot agree that the market and or institutions wont care what DW has to say. His track record is very impressive as is his perspective. I took from the interview ( subtext) that imminent merger/s is possible and potentially a large raise but not at a discount to the market. He believes it will be a potential disruptive product and that even Sales in the existing exosome research test available will accelerate by June now they are through a major distributor in US. .